These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 30852963)

  • 1. Cerebral Ischemia in Patients on Direct Oral Anticoagulants.
    Macha K; Marsch A; Siedler G; Breuer L; Strasser EF; Engelhorn T; Schwab S; Kallmünzer B
    Stroke; 2019 Apr; 50(4):873-879. PubMed ID: 30852963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prior Direct Oral Anticoagulant Therapy is Related to Small Infarct Volume and No Major Artery Occlusion in Patients With Stroke and Non-Valvular Atrial Fibrillation.
    Sakamoto Y; Okubo S; Sekine T; Nito C; Suda S; Matsumoto N; Nishiyama Y; Aoki J; Shimoyama T; Kanamaru T; Suzuki K; Mishina M; Kimura K
    J Am Heart Assoc; 2018 Sep; 7(17):e009507. PubMed ID: 30371159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Setting Comparison of Nonvitamin-K Antagonist Oral Anticoagulants Versus Vitamin-K Antagonists for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Ntaios G; Papavasileiou V; Makaritsis K; Vemmos K; Michel P; Lip GYH
    Stroke; 2017 Sep; 48(9):2494-2503. PubMed ID: 28716982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study.
    Toyoda K; Arihiro S; Todo K; Yamagami H; Kimura K; Furui E; Terasaki T; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Kameda T; Nagakane Y; Hasegawa Y; Mochizuki H; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Kario K; Sato S; Koga M;
    Int J Stroke; 2015 Aug; 10(6):836-42. PubMed ID: 25581108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-month risk-benefit profile of anticoagulation after stroke with atrial fibrillation: The SAMURAI-Nonvalvular Atrial Fibrillation (NVAF) study.
    Arihiro S; Todo K; Koga M; Furui E; Kinoshita N; Kimura K; Yamagami H; Terasaki T; Yoshimura S; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Nagakane Y; Kameda T; Hasegawa Y; Shibuya S; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Matsuki T; Homma K; Takasugi J; Tokunaga K; Sato S; Kario K; Kitazono T; Toyoda K;
    Int J Stroke; 2016 Jul; 11(5):565-74. PubMed ID: 26927811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis.
    Shahjouei S; Tsivgoulis G; Goyal N; Sadighi A; Mowla A; Wang M; Seiffge DJ; Zand R
    Stroke; 2020 Feb; 51(2):533-541. PubMed ID: 31884908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler MJ; Day JD; Mallender C; Osborn JS; Stevens SM; Weiss JP; Woller SC; Bunch TJ
    Am J Cardiol; 2016 Jul; 118(2):210-4. PubMed ID: 27236255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in anticoagulant prescribing: a review of local policies in English primary care.
    Ho KH; van Hove M; Leng G
    BMC Health Serv Res; 2020 Apr; 20(1):279. PubMed ID: 32245380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct Oral Anticoagulant Plasma Levels for the Management of Acute Ischemic Stroke.
    Marsch A; Macha K; Siedler G; Breuer L; Strasser EF; Engelhorn T; Dörfler A; Schwab S; Kallmünzer B
    Cerebrovasc Dis; 2019; 48(1-2):17-25. PubMed ID: 31484174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The relationship between stroke severity and prior direct oral anticoagulant therapy in patients with acute ischaemic stroke and non-valvular atrial fibrillation.
    Sakamoto Y; Okubo S; Nito C; Suda S; Matsumoto N; Abe A; Aoki J; Shimoyama T; Takayama Y; Suzuki K; Mishina M; Kimura K
    Eur J Neurol; 2017 Nov; 24(11):1399-1406. PubMed ID: 28799181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Extreme Obesity.
    Russo V; Cattaneo D; Giannetti L; Bottino R; Laezza N; Atripaldi U; Clementi E
    Clin Ther; 2021 Sep; 43(9):e255-e263. PubMed ID: 34366151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the cost-effectiveness of new oral anticoagulants for the prevention of stroke and systemic embolism in atrial fibrillation in a UK setting.
    Zheng Y; Sorensen SV; Gonschior AK; Noack H; Heinrich-Nols J; Sunderland T; Kansal AR
    Clin Ther; 2014 Dec; 36(12):2015-2028.e2. PubMed ID: 25438722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trends in use of warfarin and direct oral anticoagulants in atrial fibrillation in Norway, 2010 to 2015.
    Kjerpeseth LJ; Ellekjær H; Selmer R; Ariansen I; Furu K; Skovlund E
    Eur J Clin Pharmacol; 2017 Nov; 73(11):1417-1425. PubMed ID: 28735494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the efficacy of direct oral anticoagulants (DOACs) in comparison to warfarin in morbidly obese patients.
    Kalani C; Awudi E; Alexander T; Udeani G; Surani S
    Hosp Pract (1995); 2019 Oct; 47(4):181-185. PubMed ID: 31580732
    [No Abstract]   [Full Text] [Related]  

  • 16. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
    BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
    [No Abstract]   [Full Text] [Related]  

  • 17. Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: An updated systematic review and meta-analysis of randomized controlled trials.
    Ntaios G; Papavasileiou V; Diener HC; Makaritsis K; Michel P
    Int J Stroke; 2017 Aug; 12(6):589-596. PubMed ID: 28730948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation.
    Seiffge DJ; Werring DJ; Paciaroni M; Dawson J; Warach S; Milling TJ; Engelter ST; Fischer U; Norrving B
    Lancet Neurol; 2019 Jan; 18(1):117-126. PubMed ID: 30415934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients.
    Shah A; Shewale A; Hayes CJ; Martin BC
    Stroke; 2016 Jun; 47(6):1555-61. PubMed ID: 27103018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute Ischemic Stroke Outcome and Preceding Anticoagulation: Direct Oral Anticoagulants Versus Vitamin K Antagonists.
    Tavares SF; Ferreira I; Chaves V; Flores L; Correia C; Almeida J; Fonseca L; Castro Chaves P
    J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104691. PubMed ID: 32067853
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.